An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®

[1] Kanis JA(2008)FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-397

[2] Johnell O(2011)Interpretation and use of FRAX in clinical practice Osteoporos Int 22 2355-2411

[3] Oden A(2009)Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811-817

[4] Johansson H(2009)Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 1049-1054

[5] McCloskey E(2010)A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX Bone 47 729-735

[6] Kanis JA(2011)A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)) Osteoporos Int 22 2347-2355

[7] Hans D(2012)Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX J Bone Miner Res 27 1480-1486

[8] Cooper C(2008)Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 525-535

[9] Baim S(2008)Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923-1934

[10] Bilezikian JP(2009)Assessment of the effect of bazedoxifene on non-vertebral fracture risk J Bone Miner Res 24 S140-645

[1] Kanis JA(2008)FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-397

[2] Johnell O(2011)Interpretation and use of FRAX in clinical practice Osteoporos Int 22 2355-2411

[3] Oden A(2009)Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811-817

[4] Johansson H(2009)Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 1049-1054

[5] McCloskey E(2010)A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX Bone 47 729-735

[6] Kanis JA(2011)A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)) Osteoporos Int 22 2347-2355

[7] Hans D(2012)Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX J Bone Miner Res 27 1480-1486

[8] Cooper C(2008)Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 525-535

[9] Baim S(2008)Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial J Bone Miner Res 23 1923-1934

[10] Bilezikian JP(2009)Assessment of the effect of bazedoxifene on non-vertebral fracture risk J Bone Miner Res 24 S140-645